Prime Capital Investment Advisors LLC Sells 3,811 Shares of AbbVie Inc. $ABBV

Prime Capital Investment Advisors LLC lessened its position in AbbVie Inc. (NYSE:ABBV) by 3.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,698 shares of the company’s stock after selling 3,811 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in AbbVie were worth $32,620,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Burk Holdings LLC acquired a new stake in shares of AbbVie in the second quarter valued at about $30,000. Marquette Asset Management LLC increased its stake in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the period. Principia Wealth Advisory LLC increased its stake in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the period. Merkkuri Wealth Advisors LLC bought a new position in shares of AbbVie in the first quarter worth about $34,000. Finally, IMG Wealth Management Inc. lifted its position in shares of AbbVie by 3,060.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Promising Crohn’s disease results strengthen AbbVie’s pipeline. In a Phase 2a study, investigational ABBV-466, a dual-targeting therapy against IL-23 and integrin α4β7, produced higher endoscopic remission rates than either monotherapy at Week 12, with the treatment advantage widening by Week 24. The results suggest a potential future combination option in inflammatory bowel disease and helped reinforce AbbVie’s immunology strategy. AbbVie Presents Data for ABBV-466
• Positive Sentiment: Analysts see continued growth in neuroscience. AbbVie’s neuroscience franchise is projected to deliver nearly 16% revenue growth in the third quarter, supported by established products and newer Parkinson’s disease therapies. This offers another source of expansion as the company manages the loss of exclusivity for Humira. AbbVie’s Neuroscience Franchise
• Positive Sentiment: Strong cash generation supports the investment case. A comparison with Vertex highlighted AbbVie’s substantial free cash flow and its ability to navigate Humira’s patent expiration, factors that may support dividends, business development and pipeline investment. AbbVie vs. Vertex Pharmaceuticals
• Neutral Sentiment: McLaren Formula 1 partnership raises AbbVie’s visibility. The multiyear sponsorship and “Race to Innovate” campaign will promote awareness of immune-mediated diseases and provide charitable donations tied to McLaren’s championship points. The initiative is strategically positive for brand recognition but is unlikely to materially affect near-term earnings. AbbVie Named Official Pharmaceutical Partner of McLaren
• Negative Sentiment: Competitive risk remains in immunology. Reports that Rapport Therapeutics may enter a market estimated at $4.3 billion—and positive commentary surrounding Spyre Therapeutics’ ulcerative-colitis combination approach—highlight potential future competition. However, these programs remain developmental and do not appear to change AbbVie’s near-term results. Rapport Enters AbbVie Market

AbbVie Price Performance

Shares of AbbVie stock opened at $288.66 on Wednesday. The company has a market cap of $510.01 billion, a PE ratio of 81.54, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. The firm has a fifty day moving average price of $264.22 and a two-hundred day moving average price of $240.39. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on ABBV shares. Leerink Partners increased their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Rothschild & Co Redburn raised their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Cantor Fitzgerald lifted their price target on AbbVie from $285.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. Oppenheimer lifted their price target on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $225.00 price target (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.